

Wyatt
foreign Patent
Search

17/5/1 (Item 1 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014603998 **Image available**

WPI Acc No: 2002-424702/200245

XRPX Acc No: N02-333885

Neural prosthesis for implantation within eye, includes microchannels which are located within foldable substrate sup- porting integrated circuits/electrode array, for expanding substrate

Patent Assignee: MASSACHUSETTS INST TECHNOLOGY (MASI)

Inventor: RIZZO J; SHIRE D; WYATT J ; SHIRE D B; WYATT J L

Number of Countries: 022 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 6368349	B1	20020409	US 2000717738	A	20001121	200245 B
WO 200241814	A2	20020530	WO 2001US43241	A	20011120	200245
WO 200241754	A2	20020530	WO 2001US43343	A	20011119	200245

Brad
Duke

Priority Applications (No Type Date): US 2000717738 A 20001121

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
-----------	------	--------	----------	--------------

US 6368349	B1	6	A61F-002/16	
------------	----	---	-------------	--

WO 200241814	A2 E		A61F-009/00	
--------------	------	--	-------------	--

Designated States (National): CA JP

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WO 200241754	A2 E		A61B-000/00	
--------------	------	--	-------------	--

Designated States (National): CA JP

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

Abstract (Basic): US 6368349 B1

NOVELTY - The microchannels (18) are arranged within the foldable substrate for expanding the substrate. The integrated circuits/electrode array (16) are supported by the substrate.

USE - Neural prosthesis for implantation within eye for providing sufficient vision to visually handicapped people.

ADVANTAGE - The foldable substrate is the expanded state provides close opposition between the electrode array and the neural tissue, thereby providing sufficient semiconductor area to implement the power control and driving functions necessary for its operation without cutting or dragging on the retina. The use of biocompatible materials and sufficiently low currents, avoids chemical and electrochemical toxicity. The prosthesis is designed such that it can be easily inserted through a narrow incision in the sclera. If the surgeon desired to reduce or increase the rigidity of the prosthesis, gas or fluid used to inflate the prosthesis is simply added or removed.

DESCRIPTION OF DRAWING(S) - The figure shows a plan view of the inflatable prosthesis.

Integrated circuits/electrode array (16)

Microchannels (18)

pp; 6 DwgNo 1/3

Title Terms: NEURAL ; PROSTHESIS; IMPLANT; EYE; MICROCHANNEL; LOCATE; FOLD ; SUBSTRATE; PORT; INTEGRATE; CIRCUIT; ELECTRODE; ARRAY; EXPAND; SUBSTRATE

Derwent Class: P31; P32; S05; U12; U13

International Patent Class (Main): A61B-000/00; A61F-002/16; A61F-009/00
File Segment: EPI; EngPI

17/5/2 (Item 2 from file: 350)
DIALOG(R) File 350:Derwent WPIX
(c) 2003 Thomson Derwent. All rts. reserv.

013973297
WPI Acc No: 2001-457510/200149
XRAM Acc No: C01-138376

Novel antisense compounds, particularly antisense oligonucleotides for inhibiting expression of glycogen synthase kinase 3 beta in cells and for diagnosing, treating neurological and insulin regulation disorders

Patent Assignee: ISIS PHARM INC (ISIS-N)

Inventor: BUTLER M M; MCKAY R; MONIA B P; WYATT J R ; WYATT J

Number of Countries: 095 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200152862	A1	20010726	WO 2001US1085	A	20010112	200149 B
AU 200129415	A	20010731	AU 200129415	A	20010112	200171
US 6323029	B1	20011127	US 2000489765	A	20000119	200175
EP 1248633	A1	20021016	EP 2001942555	A	20010112	200276
			WO 2001US1085	A	20010112	

Priority Applications (No Type Date): US 2000489765 A 20000119

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200152862 A1 E 106 A61K-031/7088

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200129415 A A61K-031/7088 Based on patent WO 200152862

US 6323029 B1 A61K-031/7115

EP 1248633 A1 E A61K-031/7088 Based on patent WO 200152862

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

Abstract (Basic): WO 200152862 A1

NOVELTY - An antisense compound (I), 8-30 nucleobases in length targeted to a nucleic acid encoding glycogen synthase kinase 3-beta, which specifically hybridizes with and inhibits the expression of glycogen synthase kinase 3-beta, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a pharmaceutical composition (II) comprising (I).

ACTIVITY - **Neuroprotective**; nootropic; antidiabetic; antiinflammatory; cytostatic.

MECHANISM OF ACTION - Antisense therapy (claimed).

Oligonucleotides S1: TGCCGTCTTGCTCTGCTA and S2:

TGGCTTGATATAACCACACCA were designed to target different regions of the glycogen synthase kinase 3-beta RNA. All compounds were chimeric oligonucleotides, 20 nucleotides in length, composed of a central gap region consisting of 2'-deoxynucleotides flanked on both sides by five-nucleotide wings. The wings are composed of 2'-methoxyethyl.

(2'-MOE) nucleotides and the internucleoside linkages were phosphorothioate. The compounds were analyzed for their effect on human glycogen synthase kinase 3-beta mRNA levels by quantitative real-time polymerase chain reaction (PCR). The results demonstrated that S1 and S2 inhibited glycogen synthase kinase 3-beta mRNA levels by 98 % and 95 %, respectively.

USE - (I) is useful for inhibiting the expression of glycogen synthase kinase 3-beta in cells or tissues and for treating a human having a disease or condition associated with glycogen synthase kinase 3-beta, such as insulin regulation disorder, in particular diabetes and **neurological** disorder, e.g. Alzheimer's disease and bipolar illness (claimed). (I) is also useful for diagnosing diseases associated with the expression of glycogen synthase kinase 3-beta and for prophylaxis e.g. to prevent or delay infection, inflammation or tumor formation and as a research reagent.

ADVANTAGE - The antisense compound is safely and effectively administered to humans.

pp; 106 DwgNo 0/0

Title Terms: NOVEL; COMPOUND; INHIBIT; EXPRESS; GLYCOGEN; SYNTHASE; KINASE; BETA; CELL; DIAGNOSE; TREAT; **NEUROLOGICAL**; INSULIN; REGULATE; DISORDER

Derwent Class: B04; D16

International Patent Class (Main): A61K-031/7088; A61K-031/7115

International Patent Class (Additional): A61K-031/712; A61K-031/7125; C07H-021/00; C12N-005/06; C12N-005/08

File Segment: CPI

17/5/3 (Item 3 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

013967685

WPI Acc No: 2001-451899/200148

XRAM Acc No: C01-136562

New antisense compound(s) are useful to inhibit a nucleic acid molecule encoding macrophage migration inhibitory factor

Patent Assignee: ISIS PHARM INC (ISIS-N)

Inventor: COWSERT L M; MURRAY S F; **WYATT J R**; MURRAY S; **WYATT J**

Number of Countries: 095 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200153317	A1	20010726	WO 2001US1475	A	20010116	200148 B
US 6268151	B1	20010731	US 2000489869	A	20000120	200151
AU 200129537	A	20010731	AU 200129537	A	20010116	200171
EP 1248795	A1	20021016	EP 2001942631	A	20010116	200276
			WO 2001US1475	A	20010116	

Priority Applications (No Type Date): US 2000489869 A 20000120

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200153317 A1 E 105 C07H-021/04

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

US 6268151 B1 C12Q-001/68
AU 200129537 A C07H-021/04 Based on patent WO 200153317
EP 1248795 A1 E C07H-021/04 Based on patent WO 200153317
Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT
LI LT LU LV MC MK NL PT RO SE SI TR

Abstract (Basic): WO 200153317 A1

NOVELTY - An antisense compound (AC) 8 - 30 nucleotides in length targeted to a nucleic acid molecule encoding macrophage migration inhibitory factor (MMIF), where the antisense compound specifically hybridizes with and inhibits the expression of MMIF is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) a composition comprising the AC; and
- (2) the inhibition of the expression of MMIF in cells or tissues comprising contacting the cells or tissues with the antisense compound.

ACTIVITY - Nootropic; antihormonal; immunosuppressive; antiinflammatory; cytostatic.

MECHANISM OF ACTION - Macrophage migration inhibitory factor (MMIF) inhibitor. No data is given.

USE - The antisense nucleotides are useful for the treatment of a disease or condition associated with MMIF comprising the administration of a therapeutic or prophylactic amount of the antisense compound so that expression of MMIF is inhibited (claimed). The disorder is a **neurological**, hormonal, immune, inflammatory or hyperproliferative disorder (claimed).

pp; 105 DwgNo 0/0

Title Terms: NEW; COMPOUND; USEFUL; INHIBIT; NUCLEIC; ACID; MOLECULAR; ENCODE; MACROPHAGE; MIGRATION; INHIBIT; FACTOR

Derwent Class: B04; D16

International Patent Class (Main): C07H-021/04; C12Q-001/68

International Patent Class (Additional): A61K-035/00; C12N-015/85; C12P-019/34

File Segment: CPI

17/5/4 (Item 4 from file: 350)
DIALOG(R)File 350:Derwent WPIX
(c) 2003 Thomson Derwent. All rts. reserv.

013958033

WPI Acc No: 2001-442247/200147

XRAM Acc No: C01-133777

Antisense compound 8 to 30 nucleobases in length comprising a compound that is targeted to a nucleic acid molecule encoding glycogen synthase kinase 3 alpha, useful for the treatment of e.g. diabetes and hyperproliferative disorders

Patent Assignee: ISIS PHARM INC (ISIS-N)

Inventor: BUTLER M M; MCKAY R; MONIA B P; WYATT J R ; WYATT J

Number of Countries: 095 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200152865	A1	20010726	WO 2001US1411	A	20010116	200147 B
AU 200132814	A	20010731	AU 200132814	A	20010116	200171
US 6316259	B1	20011113	US 2000488856	A	20000121	200173
EP 1248635	A1	20021016	EP 2001904876	A	20010116	200276
			WO 2001US1411	A	20010116	

Priority Applications (No Type Date): US 2000488856 A 20000121

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200152865 A1 E 115 A61K-031/7115

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA
CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR
IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200132814 A A61K-031/7115 Based on patent WO 200152865

US 6316259 B1 A61K-031/7088

EP 1248635 A1 E A61K-031/7115 Based on patent WO 200152865

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT
LI LT LU LV MC MK NL PT RO SE SI TR

Abstract (Basic): WO 200152865 A1

NOVELTY - Antisense compound (I) 8 to 30 nucleobases in length targeted to a nucleic acid encoding glycogen synthase kinase 3 alpha, where the compound specifically hybridizes with and inhibits the expression of glycogen synthase kinase 3 alpha, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a composition comprising (I) and a colloidal dispersion system; and

(2) a method of inhibiting the expression of glycogen synthase kinase 3 alpha in cells or tissues comprising contacting the cells or tissues with (I).

ACTIVITY - Antidiabetic; CNS-General; Cardiovascular-General;
Cytostatic; Endocrine-General.

No biological data given.

MECHANISM OF ACTION - Glycogen synthase kinase 3 alpha inhibitor;
Antisense-Therapy.

No biological data given.

USE - (I) is useful for the treatment of a disease associated with glycogen synthase kinase 3 alpha such as diabetes, a **neurological** disorder, a hematopoietic disorder, a hyperproliferative disorder or a developmental disorder (claimed).

pp; 115 DwgNo 0/0

Title Terms: COMPOUND; LENGTH; COMPRISE; COMPOUND; NUCLEIC; ACID; MOLECULAR ; ENCODE; GLYCOGEN; SYNTHASE; KINASE; ALPHA; USEFUL; TREAT; DIABETES; DISORDER

Derwent Class: B04; D16

International Patent Class (Main): A61K-031/7088; A61K-031/7115

International Patent Class (Additional): A61K-031/712; A61K-031/7125;
C07H-021/00; C12N-005/06

File Segment: CPI

17/5/5 (Item 5 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

011033221 **Image available**

WPI Acc No: 1997-011145/199701

Related WPI Acc No: 1996-048883

XRPX Acc No: N97-009846

Low pressure neural contact structure for interfacing with tissue - has first portion for attaching to body and interconnection exhibiting weak restoring force in conjunction with geometry of second portion

Patent Assignee: MASSACHUSETTS INST TECHNOLOGY (MASI)

Inventor: EDELL D J; RIZZO J; WYATT J L

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 5575813	A	19961119	US 92943513	A	19920911	199701 B
			US 94234725	A	19940428	
			US 95394719	A	19950428	

Priority Applications (No Type Date): US 92943513 A 19920911; US 94234725 A 19940428; US 95394719 A 19950428

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 5575813	A	8	A61N-001/00	Cont of application US 92943513
				Cont of application US 94234725
				Cont of patent US 5476494

Abstract (Basic): US 5575813 A

The contact structure comprises a first portion for attachment to a first bodily location, such as the inner surface of the retina, and a second portion interconnected with the first portion via an interconnection and being held in contact with the **neural** tissue.

The interconnection exhibits a weak restoring force which in conjunction with the geometry of said second portion provides a preselected desired pressure of contact against the **neural** tissue. As adapted for the retina, the interconnection exhibits a weak restoring force developed in response to curvature of the interconnection along the inner radius of the retina.

ADVANTAGE - **Neural** tissue of the retina within which are ganglion cells to be electrically stimulated.

Dwg.1B/5

Title Terms: LOW; PRESSURE; **NEURAL** ; CONTACT; STRUCTURE; INTERFACE; TISSUE ; FIRST; PORTION; ATTACH; BODY; INTERCONNECT; EXHIBIT; WEAK; RESTORATION; FORCE; CONJUNCTION; GEOMETRY; SECOND; PORTION

Derwent Class: P34

International Patent Class (Main): A61N-001/00

File Segment: EngPI

17/5/6 (Item 6 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010551930 **Image available**

WPI Acc No: 1996-048883/199605

Related WPI Acc No: 1997-011145

XRPX Acc No: N96-041068

Low-pressure neural contact structure - has two interconnecting members contacting and anchored to body portion and contacting neural tissue respectively, and exhibiting weak restoring force between members to provide required contact pressure against neural tissue

Patent Assignee: MASSACHUSETTS INST TECHNOLOGY (MASI)

Inventor: EDELL D J; RIZZO J; WYATT J L

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 5476494	A	19951219	US 92943513	A	19920911	199605 B
			US 94234725	A	19940428	

Priority Applications (No Type Date): US 92943513 A 19920911; US 94234725 A 19940428

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 5476494	A	8	A61B-005/04	Cont of application US 92943513

Abstract (Basic): US 5476494 A

The low-pressure **neural** contact structure for contact with **neural** tissue, e.g. **neural** tissue of the retina within which are ganglion cells to be electrically stimulated includes a first portion for attachment to a first bodily location, such as the inner surface of the retina, and a second portion interconnected with the first portion via an interconnection and being held in contact with the **neural** tissue.

The interconnection exhibits a weak restoring force which in conjunction with the geometry of the second portion provides a preselected desired pressure of contact against the **neural** tissue. As adapted for the retina, the interconnection exhibits a weak restoring force developed in response to curvature of the interconnection along the inner radius of the retina.

USE/ADVANTAGE - Low-pressure **neural** contact structure for contact with **neural** tissue of retina within which are ganglion cells to be electrically stimulated in prosthetic devices. Provides adequate surface pressure for contacting **neural** tissue while minimising pressure due to contact conforming to contours of **neural** tissue.

Dwg.1/20

Title Terms: LOW; PRESSURE; **NEURAL**; CONTACT; STRUCTURE; TWO; INTERCONNECT; MEMBER; CONTACT; ANCHOR; BODY; PORTION; CONTACT; **NEURAL**; TISSUE; RESPECTIVE; EXHIBIT; WEAK; RESTORATION; FORCE; MEMBER; REQUIRE; CONTACT; PRESSURE; **NEURAL**; TISSUE

Derwent Class: P31; S05

International Patent Class (Main): A61B-005/04

File Segment: EPI; EngPI

17/5/7 (Item 7 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010276733 **Image available**

WPI Acc No: 1995-177988/199523

XRPX Acc No: N95-139814

Preferential stimulation method for stimulating neural somas over neural axons - applying positive electrical pulse to region of neural tissue consisting neural somas to be stimulated and neural axons, and preferentially stimulating somas by electrical pulse over neural axons not integral with somas

Patent Assignee: MASSACHUSETTS INST TECHNOLOGY (MASI)

Inventor: EDELL D J; RIZZO J; **WYATT J L**

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 5411540	A	19950502	US 9372320	A	19930603	199523 B

Priority Applications (No Type Date): US 9372320 A 19930603

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 5411540	A	9	A61N-001/00	

Abstract (Basic): US 5411540 A

The method for preferentially stimulating **neural** somas with respect to **neural** axons located near the somas but not integral with the **neural** somas, in a region of **neural** tissue involves positioning a stimulating electrode in the vicinity of the region of **neural** tissue and, applying a positive electrical pulse to the region of **neural** tissue including one or more **neural** somas to be stimulated and **neural** axons to lower a stimulation thresholds of the **neural** somas with respect to thresholds of the non-integral **neural** axons.

The **neural** somas of the **neural** tissue are preferentially stimulated by the positive electrical pulse over the **neural** axons not integral with the **neural** somas to be stimulated.

USE/ADVANTAGE - Preferentially stimulating **neural** somas over **neural** axons located around somas but not integral with somas. Enables local focusing of external stimulation such that it may be directed to particular soma locations for indicating location-dependent sensory information. Pulse scheme may be employed in prosthetic applications e.g retinal ganglia **neural** tissue.

Dwg.2/4

Title Terms: PREFER; STIMULATING; METHOD; STIMULATING; **NEURAL** ; **NEURAL** ; APPLY; POSITIVE; ELECTRIC; PULSE; REGION; **NEURAL** ; TISSUE; CONSIST; **NEURAL** ; STIMULATING; **NEURAL** ; PREFER; STIMULATING; ELECTRIC; PULSE; **NEURAL** ; INTEGRAL

Derwent Class: P34; S05

International Patent Class (Main): A61N-001/00

File Segment: EPI; EngPI

17/5/8 (Item 8 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

009952312 **Image available**

WPI Acc No: 1994-220025/199427

XRAM Acc No: C94-099941

XRXPX Acc No: N94-173917

Electrode assembly for detecting electro-potential in human brain surface - comprises polyester multi-fibre conductor bound with resin and impregnated with nonionic surfactant through which electrolyte flows to contact face and surface

Patent Assignee: BRITISH AEROSPACE PLC (BRAX)

Inventor: RUSSELL D D; **WYATT J C** ; YOUNG G M

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
GB 2274396	A	19940727	GB 931459	A	19930126	199427 B
GB 2274396	B	19961204	GB 931459	A	19930126	199701

Priority Applications (No Type Date): GB 931459 A 19930126

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
GB 2274396	A	19	A61B-005/04	
GB 2274396	B		A61B-005/04	

Abstract (Basic): GB 2274396 A

The assembly (1) has conductor (2) having a face (3) for making contact, via an electrolyte, with a surface of the subject or object and an electrode (4) connected to a second face or region (5) of the conductor other than the first face, the electrode providing an output signal representative of a detected electro potential. Electrolyte forms part of or is connected to the conductor so that, in operation, electrolyte is provided between the first face of the conductor and the surface of the subject or object.

The conductor is pref. an elongate bundle of side-by-side, parallel fibres, their ends providing the first and second faces. The fibres are esp. polyester, bound together with resin and impregnated with nonionic surfactant. The electrode is a metal wire, esp. silver, coated with a metal chloride, esp. silver chloride, which is in turn coated with a conducting gel layer, esp. an aq. soln. of potassium chloride and gelatine or methyl cellulose. The electrolyte is at least in part formed by a blind bore (6) in the conductor opening through its second face into which the electrode wire projects. The bore forms a reservoir for contg. electrolyte which flows along the conductor fibres to the first face.

USE/ADVANTAGE - Electrode assembly is esp. for detecting electro potential activity in a human **brain**. The assembly has lower impedance than conventional medical button electrodes and a smaller contact area with the subject surface. It does not need to be attached to the subject surface with sticking plaster and it is unnecessary to shave the subject surface.

Dwg.1/3

Title Terms: ELECTRODE; ASSEMBLE; DETECT; ELECTRO; POTENTIAL; HUMAN; **BRAIN**; SURFACE; COMPRISE; POLYESTER; MULTI; FIBRE; CONDUCTOR; BOUND; RESIN; IMPREGNATE; NONIONIC; SURFACTANT; THROUGH; ELECTROLYTIC; FLOW; CONTACT; FACE; SURFACE

Derwent Class: A96; P31; S05

International Patent Class (Main): A61B-005/04

International Patent Class (Additional): A61B-005/0478

File Segment: CPI; EPI; EngPI

17/5/9 (Item 9 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

009855757

WPI Acc No: 1994-135613/199416

Related WPI Acc No: 1991-281210; 1994-302552; 1996-285782

XRAM Acc No: C94-062799

New modified oligo-nucleotide contg guanine quartet - inhibits activity of viruses, e.g. HIV, and phospholipase A2 and modulates telomere length of chromosomes

Patent Assignee: ISIS PHARM INC (ISIS-N)

Inventor: ANDERSON K P; BENNETT C F; BROWN-DRIVER V L; CHIANG M; ECKER D J; HANECAK R C; IMBACH J L; VICKERS T A; **WYATT J R**; IMBACH J; BENNETT F C

Number of Countries: 045 Number of Patents: 019

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9408053	A1	19940414	WO 93US9297	A	19930929	199416	B
AU 9351673	A	19940426	AU 9351673	A	19930929	199432	
FI 9501467	A	19950328	WO 93US9297	A	19930929	199525	
			FI 951467	A	19950328		
NO 9501191	A	19950328	WO 93US9297	A	19930929	199526	
			NO 951191	A	19950328		
EP 672193	A1	19950920	EP 93922788	A	19930929	199542	
			WO 93US9297	A	19930929		
AU 668604	B	19960509	AU 9351673	A	19930929	199626	
EP 672193	A4	19951122	EP 93922788	A		199626	
JP 8500738	W	19960130	WO 93US9297	A	19930929	199642	
			JP 94509299	A	19930929		
NZ 256787	A	19970424	NZ 256787	A	19930929	199723	
			WO 93US9297	A	19930929		
HU 70965	T	19951128	WO 93US9297	A	19930929	199734	
			HU 95911	A	19930929		
BR 1100614	A3	19980428	BR 971100614	A	19970513	199823	
JP 2818031	B2	19981030	WO 93US9297	A	19930929	199848	
			JP 94509299	A	19930929		
NZ 314251	A	19990528	NZ 256787	A	19930929	199927	
			NZ 314251	A	19930929		
US 5952490	A	19990914	US 92954185	A	19920929	199944	
			WO 93US9297	A	19930929		
			WO 93US9297	A	19930929		
			US 95403888	A	19950612		
EP 1016715	A1	20000705	EP 93922788	A	19930929	200035	
			EP 99203835	A	19930929		
KR 172153	B1	19990201	WO 93US9297	A	19930929	200039	
			KR 95701139	A	19950324		
EP 672193	B1	20020814	EP 93922788	A	19930929	200255	
			WO 93US9297	A	19930929		
			EP 99203835	A	19930929		
CA 2145664	C	20020820	CA 2145664	A	19930929	200263	
			WO 93US9297	A	19930929		
DE 69332206	E	20020919	DE 632206	A	19930929	200269	
			EP 93922788	A	19930929		
			WO 93US9297	A	19930929		

Priority Applications (No Type Date): US 92954185 A 19920929; US 95403888 A 19950612

Cited Patents: 03Jnl.Ref; WO 9116901; WO 9116902; WO 9118004; WO 9203454; WO 9318187; WO 9323572; WO 9407367

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
WO 9408053	A1	E 144	C12Q-001/70	

Designated States (National): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE

AU 9351673 A C12Q-001/70 Based on patent WO 9408053

FI 9501467 A C07H-000/00

NO 9501191 A C07H-021/00

EP 672193 A1 E C12Q-001/70 Based on patent WO 9408053

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AU 668604	B	C07H-021/04	Previous Publ. patent AU 9351673 Based on patent WO 9408053
EP 672193	A4	C12Q-001/70	
JP 8500738	W	162 C12N-015/09	Based on patent WO 9408053
NZ 256787	A	C12N-015/11	Based on patent WO 9408053
HU 70965	T	C12Q-001/70	Based on patent WO 9408053
BR 1100614	A3	C07H-021/00	
JP 2818031	B2	64 C12N-015/09	Previous Publ. patent JP 8500738 Based on patent WO 9408053
NZ 314251	A	A61K-031/70	Div ex application NZ 256787 Div ex patent NZ 256787
US 5952490	A	C07H-021/04	CIP of application US 92954185 Subst for application WO 93US9297 Based on patent WO 9408053
EP 1016715	A1 E	C12N-015/11	Div ex application EP 93922788 Div ex patent EP 672193
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE			
KR 172153	B1	C12Q-001/70	
EP 672193	B1 E	C12N-015/11	Related to application EP 99203835 Related to patent EP 1016715 Based on patent WO 9408053
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE			
CA 2145664	C E	C12N-007/06	Based on patent WO 9408053
DE 69332206	E	C12N-015/11	Based on patent EP 672193 Based on patent WO 9408053

Abstract (Basic): WO 9408053 A

Chemically modified oligonucleotides (I) with 6-27 bases, having at least one G4 or at least two G3 sequences, plus sufficient flanking sequence to inhibit significantly the activity of a virus or of phospholipase A2 or to modulate the telomere length of a chromosome are new.

Pref. (I) has at least one phosphorothioate intersugar link and all nucleosides have the alpha anomeric configuration. Partic. (I) have the sequences: (NxG4Ny)_q; (G4NxG4)_{q'} or (NxG3-4)_{q''}Nx, x and y = 1-8; q = 1-4; q' = 1-3; q'' = 1-6.

USE - (I) are useful (1) for inhibiting activity of HIV, herpes simplex virus, human cytomegalovirus or influenza virus, both therapeutically or prophylactically; (2) for treating inflammatory and neurological disorders caused by phospholipase A2 activity (also, not claimed, in cases of hyperproliferation, malignancy, cardiovascular disease and snake bite) and (3) for inhibiting division of malignant cells (by modulating telomere length, which may also retard ageing). (I) can also be used diagnostically (not claimed).

Dwg. 0/18

Title Terms: NEW; MODIFIED; OLIGO; NUCLEOTIDE; CONTAIN; GUANINE; INHIBIT; ACTIVE; VIRUS; HIV; PHOSPHOLIPASE; MODULATE; LENGTH; CHROMOSOME

Derwent Class: B04; D16; P32; P34

International Patent Class (Main): A61K-031/70; C07H-000/00; C07H-021/00; C07H-021/04; C12N-007/06; C12N-015/09; C12N-015/11

International Patent Class (Additional): A01N-043/04; A01N-063/00; A61F-006/00; A61K-007/40; A61K-031/7125; A61L-031/00; A61P-031/12; A61P-035/00; C07H-015/12; C07H-017/00; C07H-021/02; C12N-009/99; C12P-019/34; C12Q-001/68; C12Q-001/70

File Segment: CPI; EngPI

17/5/10 (Item 10 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01485390

INFLATABLE NEURAL PROSTHESIS

AUFBLASBARE NERVENPROTHESE

PROTHESE NEURONALE GONFLABLE

PATENT ASSIGNEE:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, (210190), 77 Massachusetts Avenue,
Cambridge, MA 02139, (US), (Applicant designated States: all)

INVENTOR:

WYATT, John, L., 258 Goodman's Hill Road, Sudbury, MA 01776, (US)

SHIRE, Douglas, B., 128 Rachel Carson Way, Ithaca, NY 14850, (US)

RIZZO, Joseph, 116 Commonwealth Avenue, Boston, MA 02116, (US)

PATENT (CC, No, Kind, Date):

WO 2002041814 020530

APPLICATION (CC, No, Date): EP 2001985476 011120; WO 2001US43241 011120

PRIORITY (CC, No, Date): US 717738 001121

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE; TR

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: A61F-009/00

LEGAL STATUS (Type, Pub Date, Kind, Text):

Application: 021106 A2 International application. (Art. 158(1))

Application: 021106 A2 International application entering European
phase

LANGUAGE (Publication,Procedural,Application): English; English; English

bad date

17/5/11 (Item 11 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

01001298 **Image available**

POWER SAVING SYSTEM FOR NEURAL IMPLANT DEVICES

SYSTEME D'ECONOMIE D'ENERGIE POUR DISPOSITIFS D'IMPLANTS NEURAUX

Patent Applicant/Assignee:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY, 77 Massachusetts Avenue,
Cambridge, MA 02139, US, US (Residence), US (Nationality), (For all
designated states except: US)

Patent Applicant/Inventor:

WYATT John, 258 Goodman's Hill Road, Sudbury, MA 01776, US, US
(Residence), US (Nationality), (Designated only for: US)

KELLY Shawn, 3 Portsmouth Street, Cambridge, MA 02141, US, US (Residence)
, US (Nationality), (Designated only for: US)

Legal Representative:

HAMILTON John (agent), Choate, Hall & Stewart, Exchange Place, 53 State
Street, Boston, MA 02109, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200330991 A1 20030417 (WO 0330991)

Application: WO 2002US32509 20021010 (PCT/WO US0232509)

Priority Application: US 2001328346 20011010

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

bad date

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61N-001/378

International Patent Class: A61N-001/36; A61N-001/08; A61N-001/05

Publication Language: English

Filing Language: English

English Abstract

Circuitry for and method of power efficient operation of, and energy recovery from, tissue-stimulating electrodes having high charge capacities. Post-stimulation energy is recovered from the electrodes through a variety of techniques into circuit elements such as other electrodes, an intermediate distribution system, a power supply or any other elements, through the use of sequential switching. Energy is also recoverable from the intermediate distribution system, which preferably is comprised of one or more storage capacitors operating a different voltages. Efficient power transfer among circuit elements is effected by transferring energy while limiting element- element voltage differences and/or voltage differences between the elements and the capacitances of the electrodes.

Legal Status (Type, Date, Text)

Publication 20030417 A1 With international search report.

Set	Items	Description
S1	19	AU='ECKMILLER R':AU='ECKMILLER ROLF PROF DR'
S2	5	AU='HUNERMANN R':AU='HUNERMANN RALPH'
S3	357	AU='BECKER M':AU='BECKER M L'
S4	44	AU='BECKER M M':AU='BECKER M W'
S5	90	AU='BECKER MICHAEL':AU='BECKER MICHAEL HEINRICH'
S6	52	AU='BECKER MICHAEL J':AU='BECKER MICHAEL WILLIAM'
S7	555	S1:S6
S8	17	S7 AND (NEURA? OR NEURO? OR BRAIN?)
S9	17	IDPAT (sorted in duplicate/non-duplicate order)
S10	10	IDPAT (primary/non-duplicate records only)
S11	112	AU='WYATT J':AU='WYATT J R'
S12	13	E13,E20:E24
S13	4	AU='WYATT JOHN T':AU='WYATT JOHN THEODORE'
S14	129	S11:S13
S15	13	S14 AND (NEURO? OR NEURA? OR BRAIN?)
S16	13	IDPAT (sorted in duplicate/non-duplicate order)
S17	11	IDPAT (primary/non-duplicate records only)

? show files

File 347:JAPIO Oct 1976-2003/Jan(Updated 030506)

(c) 2003 JPO & JAPIO

File 348:EUROPEAN PATENTS 1978-2003/May W03

(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030522,UT=20030515

(c) 2003 WIPO/Univentio

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200333

(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.